Last checked at 15 Apr 2024 10:58
Faron Pharmaceuticals reappoints former finance chief on interim basis
(Alliance News) - Faron Pharmaceuticals Ltd on Monday said it appointed a new interim chief financial officer to replace the outgoing James O'Brien.
Read more
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- Stock Screeners
- Share Chat
- FX
- News & RNS
- Events
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Faron Pharma Share News (FARN)
FARN Share
Price
FARN Share
News
FARN Share
Chat
FARN Share
Trades
FARN
Live RNS
FARN Share
Charts
FARN Level 2
Console
FARN Live
Share Price
FARN Broker
Ratings
FARN Directors
Deals
FARN Financial
Diary
FARN
Fundamentals
FARN Short
Positions
FARN
Media
Faron Pharma Information
Share Price Information for Faron Pharma (FARN)
Share Price is delayed by 15 minutes
Get Live Data
Share Price:
127.50
Bid:
0.00
Ask:
0.00
Change:
0.00 (0.00%)
Spread:
15.00 (12.50%)
Open:
0.00
High:
0.00
Low:
0.00
Prev. Close:
127.50
Last checked at -
Watchlists are a member only feature
Login to your account
Don't have an account? Click here to register.Faron Pharma granted protection for IFN-beta by Finnish patent office
Mon, 31st Oct 2016 12:44
(ShareCast News) - Faron Pharmaceuticals' patent application to protect the intravenous use of interferon-beta, a cytokine protein, in a novel formulation has been accepted by the Finnish patent office that enables the company to build a global proprietary position for its Traumakine drug.The claims cover a single intravenous dose of IFN-beta at 2-15 micrograms, which is being used in on-going Traumakine drug trials in Europe and Japan for acute respiratory distress syndrome, which Faron is aiming to get approval in various territories to treat of the syndrome and other vascular dysfunctions.Acute respiratory distress syndrome, which is widespread capillary leakage and inflammation in the lungs - most often as a result of pneumonia, sepsis, or significant trauma - has a 30-45% mortality rate and does not have an approved pharmacological treatment.Earlier phase one and two trials conducted in the UK and published in the Lancet Respiratory Medicine, showed a decline in mortality at day 28 of 81%.Faron has developed the first intravenous formulation of IFN-beta to treat of vascular leakage in lungs and other central organs, which the allowed claim covers, but are not limited to acute respiratory distress syndrome.The AIM-listed company said it plans to also file application to the US patent office with same scope of protection, while in spring 2017 it will file the international Patent Cooperation Treaty to start the process in other countries.Chief executive Dr Markku Jalkanen said: "We have already granted patents for INF-beta in ischemic conditions in many countries, and these additional claims significantly extend protection for Traumakine as a drug to treat life threatening conditions like acute lung injuries up to 2036-37."
More News
15 Apr 2024 09:36
Faron Pharmaceuticals CFO stands down
(Sharecast News) - Clinical-stage biopharmaceutical company Faron Pharmaceuticals revealed on Monday that chief financial officer James O'Brien would be leaving the group to "pursue another career opportunity".
Read more8 Apr 2024 11:50
UPDATE: Faron Pharmaceuticals promotes COO to CEO as father retires
(Alliance News) - Faron Pharmaceuticals Ltd on Monday said it will promote its chief operating officer to chief executive to replace his father, the company's founder.
Read more8 Apr 2024 11:28
Faron Pharmaceuticals promotes COO to CEO as founder steps back
(Alliance News) - Faron Pharmaceuticals Ltd on Monday said it will promote its chief operating officer to chief executive to replace the company's founder.
Read more8 Apr 2024 09:17
Faron Pharmaceuticals taps Juho Jalkanen for CEO
(Sharecast News) - Biopharmaceutical company Faron Pharmaceuticals named Dr Juho Jalkanen as its next chief executive officer on Monday.
Read more4 Apr 2024 11:58
Faron Pharmaceuticals secures funding to deliver next "milestones"
(Alliance News) - Faron Pharmaceuticals Ltd on Thursday said it has successfully raised funds to support the phase two study of its bexmarilimab cancer treatment.
Read more3 Apr 2024 10:59
TRADING UPDATES: Quiz sales fall, names new CEO; Byotrol eyes AIM exit
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:
Read more2 Apr 2024 13:22
UK shareholder meetings calendar - next 7 days
| Wednesday 3 April | |
| Downing Strategic Micro-Cap Investment Trust PLC | GM re approval of B share scheme |
| Quantum Exponential Group PLC | GM re delisting or potential investment in company |
| Thursday 4 April | |
| Rio Tinto PLC | AGM |
| Scottish American Investment Co PLC | AGM |
| TheWorks.co.uk PLC | GM re Main Market delisting and AIM admission |
| Friday 5 April | |
| Faron Pharmaceuticals Ltd | AGM |
| VPC Specialty Lending Investments PLC | GM re capital return via B share scheme |
| Monday 8 April | |
| Premier African Minerals Ltd | AGM |
| Tuesday 9 April | |
| Ethernity Networks Ltd | EGM re board appointments and option grants |
| Comments and questions to newsroom@alliancenews.com | |
| A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional. | |
| Copyright 2024 Alliance News Ltd. All Rights Reserved. | |
18 Mar 2024 17:09
LONDON MARKET CLOSE: Stocks downbeat before central bank rate storm
(Alliance News) - Stocks in London closed in the red on Monday, as tech gains in New York failed to make an impact ahead of several interest rate decisions from central banks across the world this week.
Read more18 Mar 2024 14:14
Faron shares jump on encouraging trial data
(Sharecast News) - Faron Pharmaceuticals announced further encouraging data from the first phase of its 'BEXMAB' trial on Monday, targeting higher-risk (HR) myelodysplastic syndrome (MDS) patients who had failed prior hypomethylating agent (HMA) treatment.
Read more18 Mar 2024 11:41
Faron Pharmaceuticals shares jump on positive data from Bexmab study
(Alliance News) - Faron Pharmaceuticals Ltd on Monday said a study showed more patients responding to treatment in a new readout of the Bexmab study focused on myelodysplastic syndrome, or MDS.
Read more18 Mar 2024 10:05
AIM WINNERS & LOSERS: Clontarf raises GBP400,000; Faron jumps
(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday.
Read more13 Mar 2024 20:49
EARNINGS AND TRADING: PensionBee nears profit; OptiBiotix Indian deal
(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:
Read more13 Mar 2024 11:52
Faron Pharmaceuticals reports year of clinical progress
(Sharecast News) - Clinical-stage biopharmaceutical company Faron Pharmaceuticals reported a year of strong progress on Wednesday, with significant overall response rates seen in both previously hypomethylating agent (HMA)-failed and higher-risk myelodysplastic syndrome (MDS) patient populations in the phase one part of the BEXMAB study.
Read more6 Mar 2024 16:06
UK earnings, trading statements calendar - next 7 days
| Thursday 7 March | |
| Admiral Group PLC | Full Year Results |
| Aviva PLC | Full Year Results |
| Beazley PLC | Full Year Results |
| Brooks Macdonald Group PLC | Half Year Results |
| Coats Group PLC | Full Year Results |
| Darktrace PLC | Half Year Results |
| Elementis PLC | Full Year Results |
| Entain PLC | Full Year Results |
| Funding Circle Holdings PLC | Full Year Results |
| Harbour Energy PLC | Full Year Results |
| ITV PLC | Full Year Results |
| Kier Group PLC | Full Year Results |
| Melrose Industries PLC | Full Year Results |
| Nexus Infrastructure PLC | Full Year Results |
| PageGroup PLC | Full Year Results |
| Physiomics PLC | Half Year Results |
| Rentokil Initial PLC | Full Year Results |
| Robert Walters PLC | Full Year Results |
| Spirax-Sarco Engineering PLC | Full Year Results |
| TT Electronics PLC | Full Year Results |
| Tyman PLC | Full Year Results |
| Friday 8 March | |
| Informa PLC | Full Year Results |
| Just Group PLC | Full Year Results |
| LMS Capital PLC | Full Year Results |
| Stelrad Group PLC | Full Year Results |
| Monday 11 March | |
| HgCapital Trust PLC | Full Year Results |
| Mincon Group PLC | Full Year Results |
| MTI Wireless Edge Ltd | Full Year Results |
| Tuesday 12 March | |
| BATM Advanced Communications Ltd | Full Year Results |
| Costain Group PLC | Full Year Results |
| Domino's Pizza Group PLC | Full Year Results |
| Fonix Mobile PLC | Half Year Results |
| Foresight Solar Fund Ltd | Full Year Results |
| Genuit PLC | Full Year Results |
| H&T Group PLC | Full Year Results |
| Hill & Smith PLC | Full Year Results |
| MaxCyte Inc | Full Year Results |
| Persimmon PLC | Full Year Results |
| Synthomer PLC | Full Year Results |
| Target Healthcare REIT PLC | Half Year Results |
| TI Fluid Systems PLC | Full Year Results |
| TP ICAP Group PLC | Full Year Results |
| Wednesday 13 March | |
| 4imprint Group PLC | Full Year Results |
| Advanced Medical Solutions Group PLC | Full Year Results |
| Balfour Beatty PLC | Full Year Results |
| Centaur Media PLC | Full Year Results |
| Faron Pharmaceuticals Ltd | Full Year Results |
| Ferrexpo PLC | Full Year Results |
| Gym Group PLC | Full Year Results |
| Hochschild Mining PLC | Full Year Results |
| IP Group PLC | Full Year Results |
| Keywords Studios PLC | Full Year Results |
| Kin & Carta PLC | Half Year Results |
| Metro Bank Holdings PLC | Full Year Results |
| Nexteq PLC | Full Year Results |
| PensionBee Group PLC | Full Year Results |
| Public Policy Holding Co Inc | Full Year Results |
| Seraphim Space Investment Trust PLC | Half Year Results |
| Supermarket Income REIT PLC | Half Year Results |
| Trainline PLC | Trading Statement |
| Vaalco Energy Inc | Full Year Results |
| Comments and questions to newsroom@alliancenews.com | |
| A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional. | |